FRANKFURT (dpa-AFX) - After the recent stabilization, the shares of Sartorius slipped again on Thursday on their way towards the low for the year at 264.90 euros. At 271.80 euros, the shares of the biotech supplier were a good 7 percent lower than the day before. The shares of subsidiary Sartorius Stedim Biotech also came under pressure again on Euronext. UBS expert Matthew Weston came away from a dinner with the management in the run-up to the Capital Markets Day with a thoroughly positive impression. The aim was to explain the problems in the first quarter to investors and make the quarterly trends more predictable.

Sartorius had been punished in mid-April for the results of the first quarter. In particular, the recovery in the bioprocess area had disappointed. According to Weston, management remains very optimistic about the medium to long-term potential of this area. This will also be underlined at the Capital Markets Day./ag/stk